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Introduction: Interferon alpha (IFN-α) has a complex role in autoimmunity, in that it may both enhance and
prevent inflammation. We have previously shown that the presence of IFN-α at sensitization protects against
subsequent antigen-triggered arthritis. To understand this tolerogenic mechanism, we performed a descriptive,
hypothesis-generating study of cellular and humoral responses associated with IFN-α-mediated protection against
arthritis.
Methods: Arthritis was evaluated at day 28 in mice given a subcutaneous injection of methylated bovine serum
albumin (mBSA), together with Freund adjuvant and 0 to 5,000 U IFN-α at days 1 and 7, followed by intraarticular
injection of mBSA alone at day 21. The effect of IFN-α on mBSA-specific IgG1, IgG2a, IgG2b, IgA, and IgE was evaluated
by enzyme-linked immunosorbent assay (ELISA). Cytokines in circulation and in ex vivo cultures on mBSA restimulation
was evaluated with ELISA and Luminex, and the identity of cytokine-producing cells by fluorescence-activated cell
sorting (FACS) analysis.
Results: Administration of IFN-α protected mice from arthritis in a dose-dependent manner but had no effect on
antigen-specific antibody levels. However, IFN-α did inhibit the initial increase of IL-6, IL-10, IL-12, and TNF, and
the recall response induced by intraarticular mBSA challenge of IL-1β, IL-10, IL-12, TNF, IFN-γ, and IL-17 in serum.
IFN-α decreased both macrophage and CD4+ T cell-derived IFN-γ production, whereas IL-17 was decreased only
in CD4+ T cells. Ex vivo, in mBSA-restimulated spleen and lymph node cell cultures, the inhibitory effect of in vivo
administration of IFN-α on proinflammatory cytokine production was clearly apparent, but had a time limit. An
earlier macrophage-derived, and stronger activation of the antiinflammatory cytokine transforming growth factor
beta (TGF-β) was observed in IFN-α-treated animals, combined with an increase in CD4+ T cells producing TGF-β
when arthritis was triggered by mBSA (day 21). Presence of IFN-α at immunizations also prevented the reduction
in TGF-β production, which was induced by the intraarticular mBSA injection triggering arthritis in control animals.
Conclusions: Administration of IFN-α has a profound effect on the cellular response to mBSA plus adjuvant, but
does not affect antigen-specific Ig production. By including IFN-α at immunizations, spleen and lymph node cells
inhibit their repertoire of antigen-induced proinflammatory cytokines while enhancing antiinflammatory TGF-β
production, first in macrophages, and later also in CD4+ T cells. On intraarticular antigen challenge, this
antiinflammatory state is reenforced, manifested as inhibition of proinflammatory recall responses and
preservation of TGF-β levels. This may explain why IFN-α protects against antigen-induced arthritis.* Correspondence: jaya.prakash.chalise@liu.se
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Type I interferon (IFN), mainly IFN-α and IFN-β, are
important antiviral cytokines that also have complex
roles in regulating inflammation. They may enhance im-
mune responses contributing to effective viral clearance,
but excessive activation of type I IFN production may
lead to chronic inflammatory conditions, such as sys-
temic lupus erythematosus (SLE) [1]. Conversely, type I
IFN can dampen inflammatory conditions such as mul-
tiple sclerosis MS [2] and experimental models of colitis
[3]. We earlier showed that injection of interferogenic
dsRNA or IFN-α into a healthy mouse joint induces
transient arthritis, which may explain why arthritis may
follow viral infections [4]. In contrast, we also showed
that if interferogenic dsRNA or IFN-α is coadministered
at repeated immunizations with methylated bovine
serum albumin, it totally prevents subsequent induction
of antigen-induced arthritis [5].
Inhibition of IFN-α may be a future treatment modality
against SLE (Sifalimumab) [6], and IFN-β is currently an
important treatment against MS [7]. The factors determin-
ing whether type I IFN will act as a pro- or anti-
inflammatory are, however, not established. To develop
safer therapeutics and to isolate the pro- or anti-
inflammatory properties of type I IFN (which could
broaden the therapeutic applications of modulation of
type I IFN signaling), it is important to understand the
mechanisms behind its pro- and antiinflammatory effects.
The pro- and antiinflammatory effects comprise both
innate and adaptive immunity. The ability of dsRNA to
induce arthritis if deposited in the joint is critically
dependent on type I IFN signaling [4] and does not re-
quire adaptive immunity [8]. In contrast, in antibody-
induced arthritis, which also can occur in mice devoid of
adaptive immunity [9], administration of IFN-α or
dsRNA protects against arthritis development [10,11].
Thus, dependent on the location and mode of adminis-
tration, the effect of IFN-α on innate immune mecha-
nisms may be both pro- and antiinflammatory.
The proinflammatory effect of IFN-α in adaptive im-
munity is well illustrated by the enhancing effect of IFN-α
on Th1-responses in SLE and models thereof [12]. By
studying the effects of IFN-α released from plasmacytoid
dendritic cells on Th-responses in SLE, Seventer and
co-workers [13] proposed a pathogenic role for IFN-α
in the triggering of the disease, whereas in established
disease, and in chronic viral infections with continued
type I IFN activation, IFN-α rather inhibits development
of proinflammatory Th responses [13]. This is manifested
by inhibited Th1 and Th17 development by IFN-α, which
may be an important factor in limiting the tissue damage
in SLE and chronic viral infections [13]. Likewise, the
therapeutic effect of type I IFN in MS, and in experimen-
tal models of inflammatory bowel disease is thought to bemediated via an inhibitory effect of type I IFN on Th1 and
Th17 development [14].
Antigen-induced arthritis (AIA) is an experimental
model of RA that involves generation of antibodies and
T cells with the capacity to transfer the disease [15]. Arth-
ritis is induced by intraarticular injection of methylated
bovine serum albumin (mBSA) in animals preimmunized
with mBSA 2 and 3 weeks earlier. If IFN-α is administered
along with the antigen at immunizations, animals fail to
develop arthritis on intraarticular injection of mBSA [5].
The work of our laboratory is focused on determining the
mechanism behind this antiinflammatory effect of IFN-α.
Downmodulation of AIA may involve modulation of the
anti-mBSA antibody repertoire from IgG2a and 2b toward
IgG1 and IgA, which are less inflammatory [16]. Likewise,
induction of mucosal IgA against CCP is associated with
less-severe RA [17]. Also, in Lyme-induced arthritis, treat-
ment with subtoxic doses of inorganic mercury clearly
ameliorates arthritis, while increasing circulating levels of
total IgE [18]. Type I IFN signaling may enhance antigen-
specific immunoglobulin levels of most IgG subclasses
[19] and IgA [20], whereas both enhancing [21] and
dampening [22] effects of IFN-α on IgE levels have been
observed.
A major contributor to joint inflammation in RA and
AIA is proinflammatory cytokines. IL-1β, IL-6, IL-17,
and TNF are found to be elevated during the develop-
ment of arthritis [23], and inhibition of TNF and IL-6
represent successful treatments of RA [24,25]. Con-
versely, antiinflammatory cytokines (for example, IL-10
[26], TGF-β [27], and IL-13 [28]) may dampen arthritis.
To understand the mechanism of IFN-α-mediated toler-
ance induction, we performed a descriptive, hypothesis-
generating study on how IFN-α affects the generation of
humoral and cellular anti-mBSA responses during the in-
duction of arthritis. We report here that IFN-α protects
against arthritis in a dose-dependent manner and imprints
leukocytes, first macrophages, and later also T-helper cells
to release antiinflammatory TGF-β, while inhibiting pro-
inflammatory cytokine release at encounter with antigen.
Methods
Mice
Female Sv129EV and A129 (mice deficient for the subunit
1 of the type I IFN receptor, IFNAR ko), B & K Universal
(Aldbrough, UK) and Balb/c (B&K, Stockholm, Sweden)
mice aged 8 to 12 weeks were kept under standard con-
ditions of temperature and light, fed standard food and
water ad libitum at the Animal Housing Unit of the
Faculty of Health sciences, Linköping University. The ex-
periment was approved by the Ethical Committee Board,
Linköping University (Dnr 77–09). All experimental pro-
cedures were performed according to the Swedish Animal
Welfare Act.
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AIA was induced as described by Van den Berg et al. [29]
with some modifications. Briefly, mice were subcu-
taneously immunized at day 1 in the flank with 200 μg
of methylated bovine serum albumin (mBSA) (Sigma-
Aldrich, Munich, Germany) emulsified in incomplete
Freund adjuvant (IFA) (Sigma, St. Louis, MO,USA), if
not indicated otherwise, with 0, 100, 1,000, or 5,000 U
of recombinant IFN-α (cat. no. 12100–1; PBL, Inter-
feron Source, Piscataway, NJ, USA). The primary
immunization was followed by a booster immunization
in the tail with 100 μg of mBSA (prepared as on day 1 in
IFA, if not indicated otherwise, with or without IFN-α)
at day 7. At day 21, 30 μg of mBSA dissolved in 20 μl
PBS was given intraarticularly in the left knee, and the
same amount of PBS was injected in the right knee. On
day 28, the mice were killed by cervical dislocation
under anesthesia. Blood samples were collected at days
0, 14, 21, and 28 from the tail vein or by cardiac punc-
ture. After centrifugation at 2,500 g, serum was sepa-
rated and stored at −20°C until use.Histologic examination
The knee joints were removed from the killed mice at
day 28 and fixed in 4% formaldehyde for 7 days,
decalcified, dehydrated, and embedded in paraffin. Sagit-
tal knee sections (4 μm) were stained with hematoxylin
and eosin. A blinded observer (JP) scored arthritis from
0 to 3, as earlier described [5].Antibody analysis
Enzyme-linked immunosorbent assay (ELISA) plates (96-
well, flat-bottomed, NUNC) were coated overnight at 4°C
with mBSA (10 μg/ml) diluted in coating buffer (50 mM bi-
carbonate/carbonate buffer). The plate was blocked with
2% casein (Sigma) overnight. Serum samples were diluted
in casein buffer 1:500 for determination of IgG1, IgG2a,
and IgG2b, and 1:20 for IgA and IgE. Then 100 μl of diluted
serum samples was added in triplicate and incubated
for 2 hours. Then 100 μl of horseradish peroxidase (HRP)-
conjugated secondary antibody goat anti-mouse IgG1,
IgG2a, IgG2b, IgE (Bethyl Laboratories, Montgomery,
AL, USA) or rat anti-mouse IgA (Southern Biotech,
Birmingham, AL, USA) was added and incubated for
2 hours. The antibodies were diluted in casein buffer
at the concentration as specified for ELISA by the manu-
facturer. Washing was performed 3 times in each step
with phosphate-buffered saline (PBS) + 0.05% Tween-20.
The plate was developed by adding 100 μl of tetra
3,3′,5,5′-tetramethylbenzidine (Sigma) solution, followed
by incubation (dark) for 15 minutes. Finally, the reaction
was stopped with 50 μl 1 M H2SO4, and the developed
color was quantified at 450 nm.Ex vivo restimulation of splenocytes and lymph node cells
The spleens and a pool of lymph nodes draining the site
of the first immunization (axillary) and the site of the
second immunization and the knee joint (brachial, pop-
liteal, and inguinal) were collected at days 0, 14, 21, and
28 of AIA. Spleens and lymph nodes were crushed and
passed through a 70-μm nylon cell strainer. Red blood
cells were lysed by using RBC-lysing solution (Sigma-
Aldrich). The cells were resuspended in Iscove Modified
Dulbecco Media (Sigma-Aldrich) supplemented with
10% heat-inactivated fetal bovine serum, 4 mM glutamine,
50 μM β-mercaptoethanol, 100 U/ml penicillin, and 0.1 mg/
ml streptomycin (Sigma-Aldrich). Then 100 μl of 2 × 106
cells per ml of the spleen and pooled lymph node cells
were cultured for 48 hours in triplicate, stimulated with
100 μl of mBSA solution (50 μg/ml). This concentration
was based on previous titration of the proliferative
response ex vivo [5].
Cytokine analysis
The levels of IL-1β, IL-6, IL-17, IL-12, IFN-γ, TNF-α, IL-
10, and IL-13 in serum collected at days 14, 21, and 28 and
in supernatants from ex vivo antigen-stimulated sple-
nocytes and lymph node cells collected after 48 hours
of culture were determined with the Multiplex Luminex
kit (Bio-Rad Laboratories, USA). The procedure was
followed strictly according to the protocol provided by
the company. The analytes were read with a Luminex-
200 machine (Invitrogen), and the data analysis was
done with MasterPlex 2010 (version 5.0.0.68). TGF-β1
levels in serum and in supernatant from splenocytes
and lymph nodes culture were determined with ELISA
(eBioscience, San Diego, CA, USA), according to manu-
facturer’s instructions.
FACS analysis
Spleen and draining lymph nodes cells isolated at days 0,
14, 21, and 28 from mice during AIA were restimulated
ex vivo with medium, mBSA, and anti-CD3 for 24 hours.
Brefeldin A (5 μg/ml) and monensin (1 μg/ml; Biolegend,
San Diego, CA, USA) were added 5 hours before harvest.
Cells were resuspended (5 million cells/ml) in PBS
containing 0.5% FBS, blocked with anti-mouse CD16/32
(Biolegend), and surface stained with anti-CD4-FITC
(Milteyeni Biotech, Lund, Sweden), anti-F4/80-AF700
(AbD Serotec, Dusseldorf, Germany), and diluted
according to the manufacturers’ recommendations.
For intracellular staining, the cells were further fixed
and permeabilized with intracellular staining buffer set
(eBioscience), according to the manufacturer’s instruc-
tions, and stained with anti-IFN-γ-APC (Biolegend), anti-
IL-17A-PE (Biolegend), and anti-TGF-β-BV (Biolegend),
diluted according to the manufacturer’s recommendations.
Between each of these steps, cells were washed 3 times in
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FACS Gallios (Beckman Coulter, Inc., Brea, CA, USA),
and data were analyzed with Kaluza Flow Analysis Soft-
ware, Beckman Coulter (version 1.2). The percentages of
IFN-γ, IL-17A, and TGF-β-positive cells among CD4- and
F4/80-positive cells (based on 10,000 to 25,000 gated
events) were determined by FMO gating, as earlier
described [30].
Statistical analysis
All the data were analyzed by using Graph Pad Prism,
Version 5.01. For comparison of arthritis severity, antibody
and cytokine levels of two groups with different treat-
ments, the nonparametric Mann–Whitney U test was
used. The effect of IFN-α on the number of cytokine-Figure 1 Interferon alpha protects against AIA in a dose-dependent m
with mBSA at days 1 and 7 in Freund incomplete adjuvant mixed with 0, 1
same antigen in PBS at day 21. At day 28, mice were killed, histochemical s
described in "Methods". (A) Percentage of animals developing arthritis. (B)
of the knee joints from each group. Severity of arthritis was evaluated by u
control (PBS) group; n = ≥6. The Fisher Exact test was performed to compa
corresponding control (PBS) group.producing cells was evaluated by the Student t test com-
paring percentages of CD4+ and F4/80+ cells (based on
10,000 to 25,000 gated events) expressing IFN-γ, IL-17,
and TGF-β. The Fisher Exact probability test was per-
formed to compare the frequency of arthritis within
two groups. Differences are judged significant when the
P value is less than 0.05.
Results
Interferon-alpha protects against AIA in a dose-
dependent manner
First we confirmed the ability of IFN-α to protect against
mBSA-induced arthritis in the previously used strain,
Sv129EV [5], and in the commonly used Balb/c strain.
Histopathologic analysis of knee joints 1 week afteranner. Female mice of strains SV129EV and Balb/c were immunized
00, 1,000, and 5,000 U IFN-α followed by intraarticular injection of
ections of the knee joint were prepared, and arthritis was evaluated as
Arthritis severity (mean ± SEM). (C) Representative histochemical slides
sing the Mann–Whitney U test (*P < 0.05; **P < 0.01, compared with
re the arthritis frequency of interferon-treated groups and the
Chalise et al. Arthritis Research & Therapy 2013, 15:R143 Page 5 of 13
http://arthritis-research.com/content/15/5/R143intraarticular injection of mBSA confirmed that inclu-
sion of 1,000 U of IFN-α at each of the two mBSA
immunizations was clearly protective (Figure 1) and
showed that the degree of arthritis protection was
dependent on the dose of IFN-α. The frequency of arth-
ritis was 90%, 60%, 15%, 7% for SV129 mice receiving
0 U, 100 U, 1,000 U, and 5,000 U of IFN-α at each
immunization, respectively. In Balb/c mice, the arthritis
incidence was 87%, 71%, 42%, and 28% in mice receiving
0 U, 100 U, 1,000 U, and 5,000 U of IFN-α, respectively
(Figure 1). Thus, the higher dose (5,000 U IFN-α) was
required to protect Balb/c mice fully from AIA; 100
units of IFN-α was found to be insufficient to protect
more than 40% of mice in any strain of mice.
IFN-α has limited effect on mBSA-specific humoral
response
Increasing levels of antigen-specific IgG1, IgG2a, and
IgG2b were detected during the course of AIA, but no
significant difference was found between control mice
and mice treated with 1,000 U IFN-α (Figure 2A,B,C) or
5,000 U IFN-α (data not shown). This was also apparent
in the absence of adjuvant, in which immunization with
mBSA alone resulted in low but significant antigen-
specific production of total IgG and IgG1, which was
not increased in the presence of 1,000 U IFN-α (see
Additional file 1: Figure S1). In contrast, endogenous
type I IFN signaling enhanced the IgG response becauseFigure 2 No effect of IFN-α on antigen-specific IgG subtypes levels in
plus IFA with or without IFN-α in 1-week intervals followed by intraarticula
14, 21, and 28 and analyzed for mBSA-specific antibodies with ELISA by usi
Black bars represent control group without IFN-α treatment, and blue bars
absorbance (450 nm) ± SEM; n ≥ 12 (pooled data of two independent expWT mice produced significantly higher levels of all ana-
lyzed IgG subtypes than did IFNΑR ko mice, although
IgG1 levels were clearly enhanced in both strains at day
28 (Figure 3).
Low, compared with IgG, but significantly higher than
day zero levels of antigen-specific IgA were detected irre-
spective of IFN-α treatment in all mice in the prechallenge
phase (Figure 4A). Thereafter, the levels steadily increased
until arthritis manifestation, but no significant difference
was observed between IFN-α-treated animals and con-
trols. Significant increases of mBSA-specific IgE levels
were detected at days 14, 21, and 28, but again, no signifi-
cant difference was found between mice treated with IFN-
α and nontreated mice (Figure 4B).
Interferon-alpha inhibits the initial increase and the
antigen-induced recall response of proinflammatory
cytokines in serum during AIA
Two weeks after mBSA sensitization, the cytokines IL-1β,
IL-6, IL-17, IL-12, IFN-γ, and TNF were increased in con-
trol mice (Figure 5, day 14). Thereafter, the level of cyto-
kines in the control group diminished in general, which
was manifested in significantly lower levels of IL-17, IL-12,
and TNF at day 21, whereas IL-1β and IFN-γ remained
unchanged between days 14 and 21 (Figure 5). One week
after intraarticular injection of mBSA in preimmunized
mice, the levels of IL-β, IL-6, IL-12, IL-17, IFN-γ, and
TNF were increased compared with day 21 (Figure 5). Theduced by mBSA plus IFA. Mice were immunized twice with mBSA
r injection of mBSA in PBS 21 days later. Serum was collected at days 0,
ng detection antibodies specific for (A) IgG1, (B) IgG2a, and (C) IgG2b.
represent the IFN-α-treated group. Data are expressed as the mean
eriments).
A B C
Figure 3 Endogenous type I IFN signaling regulates the production of antigen-specific IgG subtypes induced by mBSA plus IFA.
Wild-type mice and mice unable to express functional type I receptor (IFNΑRKO) were immunized with mBSA plus IFA twice in a 1-week interval
followed by intraarticular injection of mBSA in PBS 21 days later. Serum was collected at days 0, 14, 21, and 28 and analyzed for mBSA-specific
antibodies with ELISA by using detection antibodies specific for (A) IgG1, (B) IgG2a, and (C) IgG2b. Data are expressed as the mean absorbance
(450 nm) ± SEM; n ≥ 10. (*P < 0.05; **P < 0.01; ***P < 0.001; and ****P < 0.0001).
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in preimmunized mice that did not receive intraarticular
injection (compare black and dotted lines in Figure 5).
The described cytokine profile was altered by IFN-α in
a dose-dependent manner both in the prechallenge
phase and at the time of arthritis manifestation. First, in
mice receiving 5,000 U IFN-α at each immunization, the
production of IL-6, IL-12, and TNF was significantly
lower than in controls 2 weeks after the first immu-
nization (Figure 5, day 14), and the 1,000 U dose of IFN-
α resulted in significantly lower levels of IL-12 and a
trend of lower IL-6 and TNF (Figure 5, day 14). Second,
immunization in the presence of IFN-α clearly hampered
or totally prevented the reactivation of cytokine release
induced by intraarticular injection of mBSA. Presence
of 1,000 U at each immunization totally prevented
antigen-induced reactivation of IL-1β, IL-12, and TNF,
and significantly reduced the antigen-induced levels of
IL-17 and IFN-γ (Figure 5, day 28). Presence of 5,000 U
IFN-α prevented antigen-induced recall responses of all
proinflammatory cytokines (Figure 5, day 28).A
Figure 4 No effect of IFN-α on antigen-specific IgA or IgE levels induc
IFA with or without 1,000 U IFN-α in 1-week intervals followed by intraartic
days 0, 14, 21, and 28 and analyzed for mBSA-specific antibodies with ELISA
bars represent the control group without IFN-α treatment, and blue bars re
absorbance (450 nm) ± SEM; n ≥ 12 (pooled data of two independent expInterferon-α increases serum levels of TGF-β and prevents
antigen-induced inhibition of TGF-β production
IFN-α effectively turned down the mBSA-induced pro-
inflammatory cytokine response (Figure 5). Presence of
IFN-α affected the serum levels of antiinflammatory
IL-10 in the same way as it affected the majority of
proinflammatory cytokines (that is, inhibited the initial
activation (Figure 5, day 14) and the mBSA-induced re-
call response (Figure 5, day 28). Serum levels of IL-13
only reached above baseline on intraarticular injection of
mBSA, and this activation was inhibited only by the
higher dose of IFN-α. In apparent contrast to the effect
on proinflammatory cytokines and IL-10, the presence
of IFN-α resulted in significantly higher serum levels of
TGF-β 2 weeks after the first immunization (Figure 5).
One week later, TGF-β in the control group (that is,
without IFN-α) was level with that in the IFN-α-treated
group, but declined rapidly on intraarticular antigenic
rechallenge (compare black and dotted lines in Figure 5).
This rapid mBSA-induced decline in serum levels of
TGF-β was effectively prevented by immunization in theB
ed by mBSA plus IFA. Mice were immunized twice with mBSA plus
ular injection of mBSA in PBS 21 days later. Serum was collected at
by using detection antibodies specific for (A) IgA and (B) IgE. Black
present the IFN-α-treated group. Data are expressed as the mean
eriments).
Figure 5 IFN-α downmodulates initial activation and subsequent antigen-induced reactivation of proinflammatory cytokines but
enhances the initial activation and prevents subsequent antigen-induced inhibition of TGF-β reactivation. Mice were immunized twice
with mBSA plus IFA with or without IFN-α at 1-week intervals followed by intraarticular injection of mBSA in PBS 21 days later. Levels of IL-1β,
IL-6, IL-12, IL-17, TNF, IFN-γ, IL-10, and IL-13 were determined by Luminex, and TGF-β, by ELISA in serum collected at days 0, 14, 21, and 28 during
the course of AIA. Data are expressed as mean pg/ml ± SEM (n ≥ 6). The black line, blue line, and red line represent groups receiving 0 U, 1,000
U, and 5,000 U of IFN-α, respectively, at the time of mBSA immunizations. Mann–Whitney U test was performed to compare cytokine levels
between two groups. Animals not receiving intraarticular injection of mBSA (the dotted line) produced significantly (P < 0.05) less of all analyzed
cytokines at day 28 compared with the control group. *P < 0.05 between PBS (black) and IFN-α 1,000 U (blue). #P < 0.05 between PBS (black) and
IFN-α 5,000 U (red). The experiment was performed twice with similar results.
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treated groups had significantly higher serum levels of
TGF-β at day 28 than did control mice.
In vivo administration of interferon-α inhibits
antigen-induced release of proinflammatory cytokines
but enhances TGF-β production ex vivo
The serum cytokine profile observed during the develop-
ment of mBSA-immunity and mBSA-triggered arthritis
was heavily altered by immunization in the presence of
IFN-α (Figure 5). Also, spleen and lymph node cells
restimulated with mBSA ex vivo 2 weeks after the first
immunization produced significant amounts of IL-6, IL-
17, and TGF-β, whereas IFN-γ and IL-10 were detec-
table only in spleen cell cultures (Figure 6A,B). IL-1β,
IL-12, IL-13, and TNF were not detectable (data notFigure 6 IFN-α modulates antigen-induced cytokine production from
lymph nodes were collected from mice at days 0, 14, 21, and 28 during the
restimulated with 50 μg/ml of mBSA for 48 hours. The supernatant of the c
IL-10, IL-12, IL-13, IL-17, IFN-γ, and TNF) and ELISA (TGF-β). The data are exp
node cells (n ≥ 6). From each value, the background cytokine levels found i
black line and the blue line represent groups receiving 0 U and 1,000 U of I
U test was performed to compare cytokine levels between the two groupsshown). At this time, reactivation ex vivo of IL-6, IL-10,
IL-17, and IFN-γ, but not TGF-β, was totally inhibited in
cells from mice receiving IFN-α at immunizations. Con-
versely, at this time, TGF-β production ex vivo was sig-
nificantly enhanced in both lymph and spleen cells
isolated from IFN-α-treated mice (Figure 6A,B, day 14,
blue line).
The inhibitory effect on ex vivo cytokine production of
in vivo administration of IFN has a time limit
Spleen cells isolated from IFN-α-treated mice, whose
serum levels of proinflammatory cytokines at day 28 were
generally lower than those in control mice (Figure 5),
readily produced IL-6, IL-17, and IFN-γ on antigenic res-
timulation at day 28 (Figure 6A). This waived inhibition
was also observed in lymph node cell cultures for IL-17,splenocytes and lymph node cells ex vivo. Spleens and draining
course of AIA. Single-cell suspensions were prepared and were
ulture was analyzed for different cytokines with Luminex (IL-1β, IL-6,
ressed as mean pg/ml ± SEM (n ≥ 6) in (A) splenocytes and (B) lymph
n culture media (including fetal bovine serum) were subtracted. The
FN-α, respectively, at the time of mBSA immunizations. Mann–Whitney
(*P < 0.05; **P < 0.01).
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on ex vivo splenocyte cytokine production observed 7 to
14 days after the last injection of IFN-α (Figure 6A) was
not apparent 1 week later. Still, spleen and lymph node
cells from IFN-α-treated mice produced higher levels
than did cells from control mice of antiinflammatory
TGF-β in response to mBSA-restimulation at this time
point (significant for lymph node cells and a trend for
splenocytes).
At day 28, when the serum cytokines (except TGF-β)
levels peaked in the control group (see Figure 5),
spleen cells were unexpectedly not responsive to
mBSA-restimulation ex vivo, except for a weak ability
to produce TGF-β (Figure 6A). This loss of activity wasFigure 7 IFN-α regulates TGF-β and IFN-γ production in macrophages
nodes and spleen cells were collected from mice at days 0, 14, 21, and 28
24 hours. Brefeldin A (5 μg/ml) and monensin (1 μg/ml) were added 5 hou
TGF-β expressing lymph node cells of CD4+ cells (A-C) and F4/80+ cells (D
(G) and F4/80+ cells (H) during the course of AIA. The data shown are mea
(n ≥ 5) with similar results. *P < 0.05; **P < 0.01. Blue line, mice immunized
representative dot plot of the same cells from mice with or without IFN-α
only gated cells are depicted. F4/80+ gated cells are depicted in red, and t
cytokine-producing cells among F4/80 (red) cells.not observed in lymph node cells, which still produced
IL-17 and IL-6 on restimulation ex vivo (Figure 6B).
IFN-α regulates TGF-β and IFN-γ production in
macrophages, and TGF-β, IL-17, and IFN-γ production
in T cells
Intracellular staining for TGF-β, IL-17, and IFN-γ in
CD4+ and F4/80+ gated lymph node cells restimulated
ex vivo with mBSA for 24 hours revealed that mBSA-
immunization in the presence of IFN-α inhibited IFN-γ
in both T cells (Figure 7A, days 14 and 21) and macro-
phages (Figure 7D, day 21), whereas IL-17 production
was inhibited in CD4+ T cells (days 14 and 21, Figure 7B)
but not in F4/80+ macrophages (Figure 7E). In spleenand TGF-β, IL-17, and IFN-γ production in T cells. Draining lymph
during the course of AIA and restimulated with mBSA (50 μg/ml) for
rs before FACS analysis. (A-F) Percentage of IFN-γ, IL-17A, and
, F). (G, H) percentage TGF-β-expressing spleen cells of CD4+ cells
n values ± SEM of pooled data from two independent experiments
in the presence of IFN-α; black line, control. Below each graph is a
treatment during AIA at day 14 (A-C) and day 21 (D-H). For CD4+ cells,
he figure in the upper right quadrant represents the percentage of
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with mBSA for 24 hours, a minor decrease in macro-
phages producing IFN-γ (Additional file 2: Figure S3D,
day 14) and CD4+ T cells producing IL-17 was observed
(Additional file 2: Figure S3B, day 14). IFN-α had no
inhibiting effect on the number of IFN-γ- and IL-17-
producing cells when lymph node and spleen cells were
unstimulated (mock) or generally stimulated by anti-CD3
(see Additional file 3: Figure S2, and Additional file 2:
Figure S3).
Presence of IFN-α at immunizations clearly augmented
the number of TGF-β-producing F4/80+ macrophages, as
depicted on days 14 and 21 of AIA for lymph node cells
(Figure 7F) but had no effect on TGF-β production from
CD4+ T cells in lymph node cells (Figure 7C). This enhan-
cing effect in macrophages was not present in spleen cells,
in which instead, an increase of TGF-β-producing CD4+ T
cells was observed on day 21 (Figure 7G). The enhancing
effect of IFN-α on TGF-β production in macrophages was
also clearly apparent in mock-stimulated lymph node cells
isolated from mice immunized in the presence of IFN-α.
(Additional file 3: Figure S2F).
Discussion
We recently showed that viral RNA, or IFN-α by itself,
by activating type I IFN signaling, protects against
antigen-induced arthritis [5]. The protection is dose
dependent, and Balb/c mice required a higher dose
IFN-α than did Sv129 mice to be protected (Figure 1).
This may also reflect dose dependency, but in terms of
the strength of type I IFN signaling, which affects AIA
because IFNAR ko mice develop a much more severe
arthritis than do WT mice [5]. Type I IFN production
is critically dependent on positive feedback via the type
I IFN receptor, and Sv129 mice have a strong type I IFN
signaling, in that they can produce more IFN-α com-
pared with other strains, including Balb/c [31]. The
stronger endogenous type I IFN signaling therefore likely
explains why Sv129 mice require less IFN-α than do
Balb/c mice for protection against AIA.
The fact that IFN-α, while preventing development of
mBSA-induced arthritis, had no effect on anti-mBSA anti-
body levels, questions (but does not formally exclude) the
importance of humoral immunity in the pathogenesis of
mBSA-induced arthritis. Early work by Brackertz [15]
showed that serum from immunized mice could transfer
arthritis susceptibility, but the disease was very mild in
comparison with that observed on T-cell transfer or in
immunized mice. It was later observed that mice defi-
cient in mature B cells, and thus unable to secrete anti-
bodies, are also susceptible to mBSA-induced arthritis
[32,33]. Thus, mBSA antibodies contribute only a little,
seemingly dispensable part of the pathogenesis of
mBSA-induced arthritis.Le Bon et al. [19] showed that administration of 105 U
IFN-α/β at immunization with chicken γ-globulin en-
hances the antibody response. Although the antigens
and use of adjuvant differ, doses up to 5,000 U IFN-α
seem not to have this effect because the levels of mBSA-
specific total IgG, IgG1, IgG2a, and IgG2b did not in-
crease by immunization in the presence of IFN-α. No
enhancing effect of IFN-α was masked by the potentiat-
ing effect of IFA because IFN-α did not increase anti-
mBSA immunoglobulins when mBSA was administered
without IFA (Additional file 1: Figure S1). However, en-
dogenous type I IFN signaling does regulate the estab-
lishment of humoral immunity activated by mBSA+IFA,
as the levels of IgG1, IgG2a, and IgG2b were lower in
IFNΑR ko mice as compared with WT (Figure 3). Still,
at arthritis manifestation (day 28), IFNΑR ko mice pro-
duced significant levels of all analyzed antibodies, indi-
cating that other signaling pathways clearly play an
important role in establishing the full anti-mBSA IgG
response.
A pathogenic factor in the development of arthritis is in-
flammation driven by proinflammatory cytokines, espe-
cially TNF, IL-1β, IL-6, and IL-17 [34]. Before the profound
effect on cytokine production evoked by administration of
IFN-α is detailed and related to arthritis protection, the
general pattern of cytokines induced by immunization with
mBSA plus IFA is shortly recapitulated.
The serum cytokine pattern induced by mBSA+IFA
was characterized by a peak of proinflammatory TNF,
IL-6, IL-12, IL-17, antiinflammatory IL-10 and IL-13,
and immunomodulatory IFN-γ 2 weeks after the first
immunization, followed by a significant decrease of the
majority of these cytokines (IL-12, TNF, and IL-10, and a
trend for IL-17, IL-13, and IFN-γ). A second peak of
serum cytokine levels, concomitant with arthritis mani-
festation, was induced by intraarticular injection of
mBSA (Figure 5). In contrast, TGF-β did not follow this
pattern but was instead characterized by a delayed re-
sponse that peaked 3 weeks after the first immunization
and strikingly, rapidly declined below baseline levels on
intraarticular injection of mBSA (that is, when arthritis
was established (Figure 5)).
Interestingly, immunization in the presence of IFN-α to-
tally reversed this cytokine pattern. Interferon-α inhibited
both the initial activation and the second peak induced by
mBSA of the majority of proinflammatory cytokines
(Figure 5). In contrast, it enhanced and advanced the initial
activation, and importantly, prevented antigen-induced
downmodulation of antiinflammatory/immunomodulatory
TGF-β (Figure 5). Immunization in the presence of IFN-α
also reversed the cytokine pattern observed in ex vivo stim-
ulated leukocyte cultures, in that it inhibited the early re-
sponse of the majority of proinflammatory cytokines but
enhanced that of TGF-β (Figure 6A,B).
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proinflammatory cytokines peaked in the arthritic control
group (Figure 5), the numbers of IFN-γ- and IL-17-
containing CD4+ and F4/80 cells were generally lower than
at earlier times (Figure 7 and Additional file 3: Figure S2,
and Additional file 2: Figure S3), and mBSA-restimulated
spleen cells from these mice were totally unresponsive in
terms of releasing proinflammatory cytokines (Figure 6A,
day 28). The in vivo reactivation by mBSA challenge day
21, resulting in the second peak of proinflammatory cyto-
kines, may thus have rendered them resistant to further
mBSA stimulation. In contrast, production of TGF-β,
which was clearly inhibited in vivo at arthritis manifest-
ation in the control group (Figure 5), was not inhibited in
spleen-cell cultures stimulated ex vivo with mBSA in the
same way as proinflammatory cytokines (Figure 6A).
Similarly, whereas day 28 saw low levels of pro-
inflammatory cytokines in mice receiving IFN-α (Figure 5),
spleen cells isolated the same day were responsive to
mBSA-restimulation ex vivo (Figure 6A). At earlier times,
spleen cells restimulated ex vivo are still held back, despite
lack of IFN-α in ex vivo cultures (Figure 6A). Thus, 3
weeks after the last injection of mBSA in IFA plus IFN-α,
the inhibitory effect on proinflammatory cytokines is still
present in vivo, but if spleen cells are restimulated ex vivo,
the inhibition is waived. This shows that the effect of IFN-
α may have a time limit and be reversible, at least ex vivo.
It remains to be determined whether animals immunized
in the presence of IFN-α are resistant to mBSA-induced
increase of proinflammatory cytokines in vivo and arthritis
at later time points.
Presence of IFN-α at immunizations thus inhibited
production of the Th1-promoting cytokines IL-12 and
TNF in the early phase (Figure 5) and IFN-γ, including
macrophages producing IFN-γ at later times (Figures 5
and 7D), which is in line with the inhibitory effect of
type I IFNs on Th1 immunity (IL-12, TNF, IL-1β, and
IFN-γ signaling) in monocytes [35]. The early inhibition
of Th1-promoting cytokines, especially IL-12 (Figure 5),
may be important for the lower number of T-helper cells
(CD4+) producing the Th1 cytokine IFN-γ (Figure 7A) in
mice receiving IFN-α at immunizations. On mBSA chal-
lenge day 21, this low number of Th1 cells (Figure 7A)
may result in the inhibited mBSA recall response of IFN-γ,
IL-12, and TNF observed at day 28 in mice immunized in
the presence of IFN-α (Figure 5).
IFN-α may drive Treg development [36,37], which has
been demonstrated by administration of interferogenic
CpG-DNA that supported the development of CD4+CD25+
T cells in an IFNAR-dependent manner [38]. An impor-
tant mediator for development of both Tregs [39] and
their suppressive capacity is the antiinflammatory cytokine
TGF-β. Interestingly, TGF-β, in contrast to all other ana-
lyzed cytokines, was significantly increased in mice treatedwith IFN-α. The initial source of TGF-β that could
shape an antiinflammatory state that prevents arthritis
development is, however, not likely Tregs. Albeit not
necessarily limited to that, an early source of TGF-β
in mice treated with IFN-α was instead macrophages
(Figure 7F and Additional file 3: Figure S2F), and not
until day 21 was an increase in CD4+ T cells producing
TGF-β observed in IFN-α-treated cells, as compared with
control animals (Figure 7G). The ability of both TGF-β
and IFN-α to induce Tregs is critically dependent on the
cytokine microenvironment. At excessive inflammation
(that is, in the presence of high levels of IL-6), TGF-β in-
hibits Treg development while promoting the generation
of Th17 cells [40]. Likewise, in the presence of IL-6, CpG-
DNA-activated pDC may contribute to Th17 development
via both IFN-α and TGF-β [41]. Importantly, although
TGF-β levels were significantly higher, the levels of IL-6 at
day 14 in IFN-α-treated animals were significantly lower
than those in the control group (Figure 5). Thus, by ini-
tially (day 14) activating TGF-β (Figure 5) in macrophages
(Figure 7F), while keeping IL-6 at bay (Figure 5), type I
IFN may favor TGF-β-dependent tolerance by regulatory
T cells while preventing activation of TGF-β+ IL-6=in-
duced Th17 differentiation. Indeed, at day 14 when the
number of IL-17-producing CD4+ T cells in lymph nodes
from control animals was tripled as compared with base-
line, no significant increase was yet observed in IFN-α-
treated mice (Figure 7B). Macrophages producing IL-17
during AIA (Figure 7E and Additional file 2: Figure S3E)
were not inhibited by IFN-α, and it is therefore likely that
the inhibited IL-17 recall response in vivo in IFN-α-
treated animals is due mainly to the lower number of IL-
17-producing CD4+ T cells (day 21, Figure 7B).
Once tolerance is established, antigen-restimulation may
reactivate TGF-β production, both in vivo [42] and ex vivo
[43,44]. In contrast, if inflammation is predominant, anti-
gen restimulation may inhibit TGF-β production, produ-
cing effective immunity [45]. Likewise, in arthritic control
animals, we observed a rapid decline in TGF-β levels in
serum on intraarticular rechallenge with antigen, confir-
ming a predominant inflammatory state. In contrast, in
mice receiving IFN-α at immunizations, the decline in
TGF-β at antigen rechallenge was prevented, and the
TGF-β levels followed those of mBSA-immunized mice
not receiving intraarticular injection of mBSA (Figure 5).
The tolerance was also reflected in higher levels of TGF-β
released from mBSA-stimulated lymph node and spleen
cells from IFN-α-treated animals (Figure 6A,B). Thus, one
effect of immunization with mBSA+IFA in the presence of
IFN-α may be development of mBSA-specific tolerogenic
cells, which, on intraarticular injection, are reactivated to
produce TGF-β (Figure 6B), which prevents activation of
mBSA-induced arthritis. The increase in CD4+ T cells pro-
ducing TGF-β among spleen cells from IFN-α-treated
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together with TGF-β-producing macrophages (Figure 7H),
would give rise to the higher TGF-β levels observed in
serum (Figure 5) and lymph-node cultures (Figure 6B)
from IFN-α-treated mice at the day of arthritis manifes-
tation. Possibly, continuous release of TGF-β may exhaust
these cells, resulting in a rapid decline when assessing the
number in vitro at day 28 (Figure 7). Further supporting
a role of TGF-β in tolerance-induced protection against
arthritis is that blocking of TGF-β compromises oral
tolerance to collagen-induced arthritis [46].Conclusion
In this work, we showed that prevention of mBSA-
induced arthritis by IFN-α is independent of modified
antigen-specific antibody production but involves regula-
tion of the mBSA-specific cellular response. The tole-
rogenic state induced by IFN-α is likely induced by a
combination of inhibition of proinflammatory cytokines,
especially early IL-6 production, with early enhancement
of TGF-β-producing macrophages, which together result
in fewer IFN-γ- and IL-17-producing CD4+ T cells and
development of TGF-β-producing CD4+ T cells.Additional files
Additional file 1: Figure S1. Effect of IFN-α administration on antigenic
specific total IgG and IgG subtypes during AIA in absence of adjuvant.
Mice were injected twice with mBSA with or without 1,000 U IFN-α in
1-week intervals followed by intraarticular injection of mBSA in PBS 21
days later. Serum was collected at days 0, 14, 21, and 28 and analyzed for
mBSA-specific antibodies with ELISA by using detection antibodies
specific for total IgG, IgG1, IgG2a, and IgG2b. Black bars represent control
group without IFN-α treatment, and blue bars represent IFN-α-treated
group. Data are expressed as the mean absorbance (450 nm) ± SEM,
n ≥ 6.
Additional file 2: Figure S3. Effect of IFN-α on intracellular cytokine
expression in mock, mBSA and anti-CD3-restimulated T cells and mock
and mBSA-stimulated macrophages from splenocytes during AIA. Spleens
were collected from mice at days 0, 14, 21, and 28 during the course of
AIA and restimulated with complete media (mock) or mBSA (50 μg/ml)
or anti-CD3 (1 μg/ml) for 24 hours. Brefeldin A (5 μg/ml) and monensin
(1 μg/ml) were added 5 hours before FACS analysis. (A-F) show
percentage IFN-γ-, IL-17A-, and TGF-β-expressing spleen cells of gated
CD4+ (A-C) and F4/80+ cells (D-F). The data shown are mean values ±
SEM of pooled data from two independent experiments (n ≥ 5) with
similar results (**P < 0.01). Blue line, mice immunized in the presence of
IFN-α; black line, control.
Additional file 3: Figure S2. Effect of IFN-α on intracellular cytokine
expression in mock-stimulated macrophages and mock- and
anti-CD3-stimulated T cells from lymph nodes during AIA. Draining
lymph node cells were collected from mice at days 0, 14, 21, and 28
during the course of AIA and restimulated with complete media (mock)
or anti-CD3 (1 μg/ml) for 24 hours. Brefeldin A (5 μg/ml) and monensin
(1 μg/ml) were added 5 hours before FACS analysis. (A-F) Percentage
IFN-γ-, IL-17A-, and TGF-β-expressing lymph node cells of gated CD4+
(A-C) and F4/80+ cells (D-F). The data shown are mean values ± SEM of
pooled data from two independent experiments (n ≥ 5) with similar
results (*P < 0.05). Blue line, mice immunized in the presence of IFN-α;
black line, control.Abbreviations
AIA: Antigen-induced arthritis; dSRNA: Double-stranded RNA; IFA: Incomplete
freund adjuvant; IFN: Interferon; IL: Interleukin; mBSA: Methylated bovine
serum albumin; RA: Rheumatoid arthritis; TGF: Transforming growth factor;
TNF: Tumor necrosis factor.
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